DMTK

DermTech Inc

Healthcare


Presented:03/22/2021
Price:$62.50
Cap:$1.80B
Current Price:$0.09
Cap:$0.00B

Presented

Date03/22/2021
Price$62.50
Market Cap$1.80B
Ent Value$0.59B
P/E RatioN/A
Book Value$3.06
Div Yield0%
Shares O/S28.76M
Ave Daily Vol1,612,492
Short Int8.27%

Current

Price$0.09
Market Cap$0.00B
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.

Publicly traded companies mentioned herein: AbbVie Inc (ABBV), AstraZeneca plc (AZN), Biogen Inc (BIIB) DermTech Inc (DMTK), EXACT Sciences Corporation (EXAS), Johnson & Johnson (JNJ), L’Oreal SA (OR FP), Pfizer Inc (PFE)

Highlights

The presenter is long shares of DermTech Inc (DMTK), a commercial stage molecular diagnostics business that has developed a non-invasive diagnostic for Melanoma with a very high negative predictive value (NPV). Over the last year, DMTK has received an attractive Medicare reimbursement, picked up commercial insurance coverage from several major blues, and has received NCCN guideline listing. The presenter expects this reimbursement momentum to continue over the next 12 - 24 months, which should help the company drive sales. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.